Compare · EVOK vs NVO
EVOK vs NVO
Side-by-side comparison of Evoke Pharma Inc. (EVOK) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both EVOK and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $191.82B, about 11295.7x EVOK ($17.0M).
- Over the past year, EVOK is up 252.2% and NVO is down 45.7% - EVOK leads by 297.9 points.
- NVO has hit the wire 8 times in the past 4 weeks while EVOK has been quiet.
- NVO has more recent analyst coverage (25 ratings vs 0 for EVOK).
- Company
- Evoke Pharma Inc.
- Novo Nordisk A/S
- Price
- $10.99+0.37%
- $41.01-4.51%
- Market cap
- $17.0M
- $191.82B
- 1M return
- +2.81%
- -10.44%
- 1Y return
- +252.24%
- -45.66%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2013
- News (4w)
- 0
- 8
- Recent ratings
- 0
- 25
Evoke Pharma Inc.
Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It is developing Gimoti, a metoclopramide nasal spray that has completed Phase III clinical trials to treat symptoms associated with acute and recurrent diabetic gastroparesis in females. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beach, California.
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest EVOK
- SEC Form 15-12G filed by Evoke Pharma Inc.
- Large owner Nantahala Capital Management, Llc disposed of $1,629,683 worth of shares (148,153 units at $11.00) (SEC Form 4)
- SEC Form EFFECT filed by Evoke Pharma Inc.
- SEC Form EFFECT filed by Evoke Pharma Inc.
- SEC Form EFFECT filed by Evoke Pharma Inc.
- SEC Form EFFECT filed by Evoke Pharma Inc.
- SEC Form EFFECT filed by Evoke Pharma Inc.
- SEC Form EFFECT filed by Evoke Pharma Inc.
- SEC Form S-8 POS filed by Evoke Pharma Inc.
- SEC Form S-8 POS filed by Evoke Pharma Inc.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care